The effect and possible mechanism of enhancing endogenous Nrf2 to reduce myocardial injury in DM can be verified using the Nrf2 agonist dimethyl fumarate (DMF) and the Nrf2 inhibitor ML385 [13] or overexpressing Nrf2. Here, NFE2L2 is linked to diabetes mellitus.